UK Science Gets More Post-Brexit Love From GlaxoSmithKline, Other Drugmakers
Published: Dec 06, 2017
LONDON (Reuters) - Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government’s industrial strategy plans after Brexit.
The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union.
Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.